Timeliness is key to influencing the utility of evaluation and research findings and has given rise to a range of rapid evaluation and appraisal approaches. However, issues in the design, ...
The primary objective of this study was to identify clinical risk factors associated with EOS by comparing neonates diagnosed with EOS to matched controls without early-onset sepsis (EOS). Conditional logistic regression was ...
The objective of this study was to assess the risks of perinatal emergency department (ED) use, hospitalisation and severe maternal morbidity or mortality (SMM-M) associated with preconception MCC, according to the ...
This study aimed to describe the prevalence of exposure to traumatic events and post-traumatic stress disorder (PTSD) in pregnant women attending antenatal care (ANC) in rural Ethiopia. The authors hypothesised that antenatal ...
AI for Global Health Research Community of Practice: Global In-Person Engagement The AI4GH Community of Practice is actively engaging across regions through in-person events, creating spaces for collaboration and shared ...
On Sept 8, 2025, West African Ministers of Health pledged their joint commitment to advance development of, and readiness for, much-needed vaccines against Lassa fever in recognition of the significant regional health security threat posed by the disease Read more
CEPI has announced a funding opportunity to develop innovative analytical technologies for vaccines. The goal is to reduce vaccine development, manufacturing, and release times; lower costs, improve equitable deployment in Low to Middle-Income Countries, and enhance analytical insights for vaccines. Read more
CEPI is pleased to announce that two leading scientific organizations, the International Vaccine Institute (IVI) and the Korea Disease Control and Prevention Agency (KDCA), have officially joined the CLN. The network now comprises 20 facilities... Read more
A global consortium led by Danish biotech AdaptVac is developing a vaccine that combines AI-designed immunogens, components that trigger immune response, with AdaptVac’s virus-like particle platform, which mimics real viruses to safely stimulate immunity against multiple deadly filoviruses. Read more
The objective of the RPP is to leverage investments for advanced-stage clinical development of CEPI's portfolio vaccines and support countries in key regions to generate emergency evidence in future outbreaks Read more
This article delves into the challenges and potential solutions, complemented by several case studies, concerning the establishment of robust and resilient vaccine manufacturing and supply chains in low- and middle-income countries Read more
Resources
In collaboration with TGHN, CEPI created this playbook to bring together the many tools, resources and materials generated for pandemic preparedness and response from the COVID-19 pandemic. The first (Regulatory) chapter is now available.
TRANSVAC Academy offers training modules in vaccine R&D including grant management, statistics, cytometry and advanced process development. CEPI funded scholarships are provided to selected applicants from LMICs.
SPEAC is a CEPI and Brighton Collaboration project. SPEAC provides vaccine safety tools, resources, and expertise throughout the vaccine development process to enhance safety and build confidence in vaccines.
Monitoring Vaccine Performance against SARS CoV-2 Variants
The IVAC COVID-19 Vaccine Effectiveness Project (a CEPI- funded global systematic review which also includes neutralization capacity) outputs are publicly available on VIEWhub to assist all policy makers
International Pandemic Preparedness Secretariat
The IPPS serves to join up relevant states, the private sector, and global health institutions in support of the 100 Days Mission, across vaccines, therapeutics, and diagnostics. It performs a global annual progress review related to the 100 DM which feeds into implementation reports.
Vaccine Development
Process Maps
The UK Vaccine R&D Network has developed vaccine development maps to show key stages in human and veterinary vaccines development up to Phase III clinical trials. These process maps and associated case studies provide support in understanding key stages in vaccine development and where bottlenecks could cause delays.
